We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Interfering RNA Technology Used for Chemotherapy Sensitivity Screening

By Biotechdaily staff writers
Posted on 24 Apr 2007
Cancer researchers have combined a high-throughput cell-based one-well/one-gene screening platform with a genome-wide synthetic library of chemically synthesized small interfering RNAs to identify genes related to the sensitivity of cancer cells to the chemotherapeutic drug paclitaxel.
Paclitaxel disrupts microtubule function, inhibiting cell replication. More...
One of the roles of normal microtubules is to aid in the replication of cells, and paclitaxel promotes the formation of microtubules that do not function properly, thus disrupting this function and inhibiting cell replication. The drug is used in patients who have ovarian cancer carcinoma alone, and in combination with such platinum-containing drugs as cisplatin or carboplatin. Paclitaxel is also used to treat breast cancer that has recurred or progressed following treatment with other drugs. It is also used to treat non-small cell lung carcinoma in combination with cisplatin in cases where surgery or radiation is not possible. Paclitaxel is also used to treat AIDS-related Kaposi's sarcoma.
Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) used isolated NCI-H1155 human non-small-cell lung cancer cells in a high-throughput 96-well array along with four siRNAs targeting a single gene in each well. Paclitaxel was added to each well for two days, and by examining the survival of the cells in each well, the investigators determined which genes were involved in affecting the cells'sensitivity to the drug.
Results published in the April 12, 2007, edition of Nature revealed that a panel of 87 genes represented major focal points of the autonomous response of cancer cells to paclitaxel's abrogation of microtubule dynamics. Several of these genes sensitized lung cancer cells to paclitaxel concentrations 1,000-fold lower than otherwise required for a significant response.
"Being able to do this in human cells, and being able to do it fast – this is very powerful,” said senior author Dr. Michael White, professor of cell biology at the University of Texas Southwestern Medical Center. "The idea of the screen was to be able to take advantage of the new generation of technology to silence any gene we want. That is the power of a genome-wide screen - you go in without any expectations and let the data tell you what is important. Chemotherapy is a very blunt instrument, it makes people sick, and its effects are very inconsistent. Identifying genes that make chemotherapy drugs more potent at lower doses is a first step toward alleviating these effects in patients.”


Related Links:
University of Texas Southwestern Medical Center

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Electrolyte Analyzer
BKE-B
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.